Compare Novartis AG (NVS) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Novartis AG trades at $152.64 (market cap $295.37B), while Global X NASDAQ 100 Covered Call ETF trades at $18.18. The key difference: Novartis AG pays a 3.07% dividend while Global X NASDAQ 100 Covered Call ETF pays none, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | QYLD | |
|---|---|---|
Market Cap | $295.37B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $168.62 | $18.52 |
52-Week Low | $119.31 | $16.46 |
Enterprise Value | $336.69B | — |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $152.54, down 2.71% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates of $2.17 with $2.41 actual, driven by oncology drug performance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%. Analyst consensus is mixed with 24% buy, 68% hold, and 8% sell ratings among 25 analysts.
The outlook is cautiously optimistic, supported by a robust drug pipeline and recent earnings strength, but risks include generic competition pressure on key drugs like Entresto and rising debt levels. The stock presents a stable investment opportunity with solid profitability, though growth may be tempered by industry headwinds.
QYLD trades at $18.185, showing modest daily gains of 0.19% with a bullish technical signal from moving averages despite overbought RSI conditions. The ETF maintains its covered call strategy focus, generating high dividend yields around 12% through systematic options writing on Nasdaq-100 components. Recent dividend payments of $0.18-$0.19 per share demonstrate consistent income distribution to shareholders.
The outlook remains balanced between high income generation and growth limitations. While the 12% yield attracts income-focused investors, long-term underperformance versus the underlying index presents a key trade-off. Market sentiment is divided between yield attractiveness and capital appreciation concerns, requiring careful consideration of investment objectives and risk tolerance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
